124 related articles for article (PubMed ID: 1782355)
21. Antinociceptive activity of [beta-methyl-2', 6'-dimethyltyrosine(1)]-substituted cyclic [D-Pen(2), D-Pen(5)]Enkephalin and [D-Ala(2),Asp(4)]Deltorphin analogs.
Bilsky EJ; Qian X; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 2000 Apr; 293(1):151-8. PubMed ID: 10734164
[TBL] [Abstract][Full Text] [Related]
22. Selective opioid dipeptides.
Temussi PA; Salvadori S; Amodeo P; Bianchi C; Guerrini R; Tomatis R; Lazarus LH; Picone D; Tancredi T
Biochem Biophys Res Commun; 1994 Feb; 198(3):933-9. PubMed ID: 8117299
[TBL] [Abstract][Full Text] [Related]
23. Refinement of conformational preferences of Leu enkephalin and Tyr-Gly-Gly-Phe by 15N n.m.r.: chemical shifts and vicinal coupling constants.
Garbay-Jaureguiberry C; Marion D; Fellion E; Roques BP
Int J Pept Protein Res; 1982 Nov; 20(5):443-50. PubMed ID: 7174208
[TBL] [Abstract][Full Text] [Related]
24. Comparison of conformational properties of linear and cyclic delta selective opioid ligands DTLET (Tyr-D X Thr-Gly-Phe-Leu-Thr) and DPLPE (Tyr-c[D X Pen-Gly-Phe-Pen]) by 1H n.m.r. spectroscopy.
Belleney J; Roques BP; Fournie-Zaluski MC
Int J Pept Protein Res; 1987 Sep; 30(3):356-64. PubMed ID: 3692682
[TBL] [Abstract][Full Text] [Related]
25. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
26. Enkephalin analogues containing beta-naphthylalanine at the fourth position.
Mierke DF; Said-Nejad OE; Schiller PW; Goodman M
Biopolymers; 1990 Jan; 29(1):179-96. PubMed ID: 2158358
[TBL] [Abstract][Full Text] [Related]
27. Opioid receptor selectivity of beta-endorphin in vitro and in vivo: mu, delta and epsilon receptors.
Shook JE; Kazmierski W; Wire WS; Lemcke PK; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1988 Sep; 246(3):1018-25. PubMed ID: 2843623
[TBL] [Abstract][Full Text] [Related]
28. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands.
Kramer TH; Davis P; Hruby VJ; Burks TF; Porreca F
J Pharmacol Exp Ther; 1993 Aug; 266(2):577-84. PubMed ID: 8394911
[TBL] [Abstract][Full Text] [Related]
29. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
30. Proposals for the mu-active conformation of the enkephalin analog Tyr-cyclol(-N gamma-D-A2-bu-Gly-Phe-Leu-).
Maigret B; Fournie-Zaluski MC; Roques B; Premilat S
Mol Pharmacol; 1986 Mar; 29(3):314-20. PubMed ID: 3005838
[TBL] [Abstract][Full Text] [Related]
31. Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies.
Deschamps JR; George C; Flippen-Anderson JL
Biopolymers; 1996; 40(1):121-39. PubMed ID: 8541444
[TBL] [Abstract][Full Text] [Related]
32. Conformational analysis of the biologically active cyclic analog of beta-casomorphin H-Tyr-cyclo[D-OrnPheProGly].
Kostetsky PV; Arkhipova SF
Biochemistry (Mosc); 1999 Sep; 64(9):1005-11. PubMed ID: 10521717
[TBL] [Abstract][Full Text] [Related]
33. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
Mitrovic I; Napier TC
J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
[TBL] [Abstract][Full Text] [Related]
34. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
35. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Szücs M; Boda K; Gintzler AR
J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
[TBL] [Abstract][Full Text] [Related]
36. Folded conformations of the delta-selective opioid dermenkephalin with head-to-tail interactions. A simulated annealing study through NMR restraints.
Naim M; Nicolas P; Baron D
Int J Pept Protein Res; 1996 May; 47(5):353-60. PubMed ID: 8791158
[TBL] [Abstract][Full Text] [Related]
37. Conformation-activity relationships of cyclic dermorphin analogues.
Wilkes BC; Schiller PW
Biopolymers; 1990 Jan; 29(1):89-95. PubMed ID: 2158362
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the bioactive form of linear peptide antagonists at the omega-opioid receptor.
Chao TM; Perez JJ; Loew GH
Biopolymers; 1996 Jun; 38(6):759-68. PubMed ID: 8652796
[TBL] [Abstract][Full Text] [Related]
39. Conformational-energy studies of tetrapeptide opiates. Candidate active and inactive conformations.
Loew G; Hashimoto G; Williamson L; Burt S; Anderson W
Mol Pharmacol; 1982 Nov; 22(3):667-77. PubMed ID: 7155126
[TBL] [Abstract][Full Text] [Related]
40. Conformational analysis of beta-methyl-para-nitrophenylalanine stereoisomers of cyclo[D-Pen2, D-Pen5]enkephalin by NMR spectroscopy and conformational energy calculations.
Shenderovich MD; Kövér KE; Nikiforovich GV; Jiao D; Hruby VJ
Biopolymers; 1996 Feb; 38(2):141-56. PubMed ID: 8589249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
